Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Investor Presentation (April 2016)

15 slides from Alembic Pharmaceuticals's investor presentation, April 2016

  1. Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation

    Alembic Pharmaceuticals Ltd Investor Presentation April-2016

  2. Slide 2: Contents

    Contents 1. Milestones 2. Yearly Highlights 3. Quarterly Highlights 4. Business - International - India Branded 5. Strategy 6. Financials - Annual - Latest Quarter

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe

  4. Slide 4: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facilities 2007 Acquired Dabur’s Indian cardiology, GI and gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed. 2012 Formed a JV for NCE research Launched first NDA

  5. Slide 5: Yearly Highlights - FY16

    Yearly Highlights - FY 16 Financial Highlights India Branded Formulations (Rs. 11036 mn)  Net Sales up 54% to Rs 31812 mn  Business grew by 13 %  Specialty Segment grew by 20% and Acute  EBITDA margins at 32% at Rs 10060 mn Segment grew by 4%. Price reduction by NPPA led to lower growth  Net Pr

  6. Slide 6: Quarterly Highlights – Q4 FY16

    Quarterly Highlights – Q4 FY 16 Financial Highlights India Branded Formulations (Rs. 2596 mn)  Net Sales up 25% to Rs 6342 mn  Business grew by 12%  Specialty Segment grew by 13% and Acute  EBITDA margins at 23% at Rs 1433 mn Segment grew by 7%.  Net Profit up 30% to Rs 912 mn  Strengthening t

  7. Slide 7: Business

    Business Sales CAGR% Rs 15bn Rs 32bn 21% Manufacturing: 16% 25% API 9% Formulation: Baddi and Sikkim for India market 38% FDA approved Oral Solids in Vadodara Doubled capacity in 2014 53% India 12% API: 3 FDA approved facilities in Vadodara 46% Expansion in 2015 22% International 46% FY12 FY16 R&D:

  8. Slide 8: International Formulations

    International Formulations Sales (Rs bn) ANDA Filed Filings: 76 Approval: 47* 14.6 13 * Incl 5 tentative CAGR 46% 8 7 7 5.6 5.9 4 3.2 3.0 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 R&D Spend (Rs bn) Milestones and Update 10.9 7.0 6.7 4.8 5.1  Focus on day-1 launches 3.5 Aripiprazole R&D%  U

  9. Slide 9: India Branded

    India Branded Sales (Rs bn) Marketing Organisation CAGR 14% 11.0 9.8  5000 + marketing team 8.5 Added 1000 over last two years 7.5 6.6  17 marketing divisions Added new divisions in gynaecology, cardiology , GI, urology  170 products Launch 20-25 products every year FY12 FY13 FY14 FY15 FY16 Thera

  10. Slide 10: Therapy-wise Performance FY16

    Therapy-wise Performance FY16 MAR MAT 2016 MAR MAT 2015 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 14 2.04 32 36 13 1.77 32 31 Anti Diabetic 20 1.64 38 34 20

  11. Slide 11: Strategy

    Strategy Competitive position Growth drivers Skills US: Rapidly expand breadth and quality of pipeline Doubled internal OSD grid, half of grid is external – injectable, dermatology and ophtahalmics High Partnerships to gain time and leverage financial resource Build manufacturing capacities rapidly,

  12. Slide 12: Financials – 5 years

    Financials – 5 years Sales (Rs bn) EBITDA (Rs bn) Margins% 32% 31.8 17% 19% 19% CAGR 21% 15% 10.1 20.7 18.7 14.7 15.3 4.0 3.6 2.2 2.5 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 Net Profit (Rs bn) Capital employed (Rs bn) 23% ROCE% 53% 31% 40% 30% Margins% 13% 14% 25% 11% 7.2 9% 17.8 11.9 2.8

  13. Slide 13: Financials

    Financials Sales (Rs bn) EBITDA (Rs bn) 31.8 54% 10.1 150% 20.7 25% 4.0 46% 6.3 1.0 1.4 5.1 Q4FY15 Q4FY16 FY15 FY16 Q4FY15 Q4FY16 FY15 FY16 PAT (Rs bn) Business Sales 17% 18% 16% 7.2 26% 154% 38% 52% 53% API 44% India International 2.8 30% 46% 31% 30% 29% 0.7 0.9 Q4FY15 Q4FY16 FY15 FY16 Q4FY15 Q4FY1

  14. Slide 14: Latest Shareholding Pattern

    Latest Shareholding Pattern % of Total Shareholding 13 Promoter & Promoter group 13 FI/FII/MF Public 74 Market capitalization INR 113 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders >50 K Free float market INR 29 bn capitalization

  15. Slide 15: Thank You

    THANK YOU

Alembic Pharmaceuticals — Investor Presentation (April 2016) on 6ix